Challenge studies

FluSure XP Challenge studies Combinations Vaccination timing and safety Amphigen advantage

Demonstrated protection

Challenge studies are considered the gold standard of determining vaccine effectiveness. The following are challenge studies and supporting research performed to evaluate the effectiveness of FluSure XP^® in pigs challenged with field strains.

Delta 1 H1N2

Challenged with Delta 1 H1N2, pigs vaccinated with updated FluSure XP showed:¹

Reduced clinical signs of flu
Reduced viral shedding
Reduced lung lesions
Increased antibody titers against Delta 1 H1N2

View the FluSure XP: Delta 1 H1N2 Challenge Study Technical Update for complete trial design, results and discussion.

Alpha H1N1

A university study showed that pigs vaccinated with FluSure XP were protected against Alpha H1N1, a strain that is antigenically different from the strain contained in the vaccine.²

Beta H1N1

A university study showed that pigs vaccinated with FluSure XP were protected against Beta H1N1, a strain that is antigenically different from the strain contained in the vaccine.^3,4

Gamma H1N1

Studies showed a reduction in viral shedding when pigs vaccinated with FluSure XP were challenged with Gamma H1N1.⁵

Delta 2 H1N1

When pigs vaccinated with FluSure XP were challenged with Delta 2 H1N1, the vaccine:

Reduced lung lesions and viral shedding⁶
Simulated circulating HI antibody titers⁶

Cluster IV H3N2

When pigs vaccinated with FluSure XP were challenged with Cluster IV H3N2, the vaccine:

Reduced lung lesions and viral shedding⁷
Simulated circulating HI antibody titers⁷

Duration of immunity

A duration of immunity of at least 10 weeks, as demonstrated by a reduction in lung lesions, has been demonstrated against respiratory disease caused by SIV H3N2.⁸

View the following Technical Bulletins for more information.

FluSure XP: Research-backed Swine Influenza Virus (SIV) Vaccine for Combating Rapidly Evolving SIV Viruses

Efficacy of FluSure XP in pigs challenged with either a heterologous reassortant H3N2 or H1N1 swine influenza virus

References:
1. Data on file, Study Report No. 3127R-60-10-917, Pfizer Inc.
2. Kitikoon P, Nilubol D, Vincent A, Yu S, Erickson B, Janke B, Hoover T, Sornsen S, Thacker E. Immune response and effect of maternal antibody interference on vaccination with a bivalent swine influenza vaccine. Proceedings of the 18th IPVS Congress. Hamburg, Germany. 2004;1:386.
3. Gramer M. Epidemiology of swine influenza and implications of reassortment. 2004 Allen D. Leman Swine Conference. 2004; p69-73.
4. Rapp-Gabrielson VJ, Wicklund E, Ficken M. Efficacy of FluSure^® against challenge with heterologous reassortant swine influenza H1N1 viruses. 2005 Allen D. Leman Conference
2005;32 (Supplement):14.
5. Data on file, Study Report No, 2124C-60-00301-060, Pfizer Inc.
6. Data on file, Study Report No. 3121R-60-07-538, Pfizer Inc.
7. Data on file, Study Report No. 3121R-60-07-529, Pfizer Inc.
8. Data on file, Study Report No. 2124H-60-02-019, Pfizer Inc.